Oct 8 (Reuters) – Vir Biotechnology, Inc.: * VIR BIOTECHNOLOGY ANNOUNCES PSMA-TARGETED PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 RECEIVED FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF PROSTATE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 8 (Reuters) - * STABLE ASSET MANAGEMENT: ANNOUNCED A $100 MILLION SEED INVESTMENT TO…
IMF: SIGNIFICANT PROGRESS WAS MADE DURING MISSION IN CONGO, DISCUSSIONS WILL CONTINUE IN THE NEXT…
VIDEO SHOWS: COMMENTS FROM FIFA PRESIDENT GIANNI INFANTINO AND CAF PRESIDENT PATRICE MOTSEPE DURING PRESENTATION…
Surat (Gujarat) [India], October 8: The Man-Made Textiles Research Association (MANTRA) has completed 49 glorious…
The Canadian dollar weakened against the greenback on Thursday, and the yield on benchmark government…
By Kavya Balaraman Oct 8 (Reuters) - Technology companies and utilities are increasingly exploring ways…